Sanofi and Regeneron’s next wannabe blockbuster tagged ‘priority’ by Regulators
FDA has accepted the application for atopic dermatitis candidate dupilumab, from Sanofi and Regeneron, and have given it a priority review tag that should hasten its trip to approval. Dupilumab has already shown it can beat out those topical steroids, too. In June, its makers rolled out Phase III data showing that a dupilumab/corticosteroid combo topped steroids alone. analysts see dupilumab generating more than $2.5 billion a year–with some predicting up to $4 billion or $5 billion.
Allele receives NIH grant to develop new antibody therapy for Alzheimer’s disease
Allele Biotechnology and Pharmaceuticals (Allele) has secured a grant from the US National Institutes of Health’s (NIH) National Institute on Aging to develop a new antibody therapy for Alzheimer’s disease. Allele will develop a panel of antibodies that identify this protein, one of which would be used as a therapeutic drug candidate. The antibodies will feature a distinct shape and size, allowing them to pass the blood-brain barrier to reach the critical areas of the brain. Allele researchers also aim to modify and engineer each antibody to enhance its therapeutic potential.
